Veru Inc. (VERU) Income Statement Analysis

See more : SSHT S&T Group Ltd. (SSHT) Income Statement Analysis – Financial Results

Complete financial analysis of Veru Inc. (VERU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Veru Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Sensirion Holding AG (SENS.SW) Income Statement Analysis – Financial Results
True Partner Capital Holding Limited (8657.HK) Income Statement Analysis – Financial Results
Genworth Financial, Inc. (GNW) Income Statement Analysis – Financial Results
Sun Yad Construction Co.,Ltd (1316.TW) Income Statement Analysis – Financial Results
Uniden Holdings Corporation (6815.T) Income Statement Analysis – Financial Results

Veru Inc. (VERU)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.verupharma.com

About Veru Inc.

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990
Revenue	16.89M	16.30M	39.35M	61.26M	42.59M	31.80M	15.86M	13.66M	22.13M	32.60M	24.49M	31.46M	35.03M	18.57M	22.22M	27.54M	25.63M	19.32M	14.82M	11.16M	8.83M	9.05M	8.42M	6.72M	5.77M	4.72M	5.45M	2.92M	2.06M	2.20M	16.20M	12.50M	11.20M	13.10M	10.70M
Cost of Revenue	11.03M	8.73M	8.76M	13.33M	11.81M	10.15M	7.08M	6.64M	8.78M	13.63M	11.37M	13.95M	14.41M	8.70M	9.30M	14.03M	14.90M	12.16M	9.33M	6.37M	5.21M	5.46M	4.86M	5.34M	3.60M	3.31M	5.27M	3.48M	3.68M	2.50M	7.50M	6.90M	6.10M	7.20M	6.10M
Gross Profit	5.85M	7.57M	30.59M	47.93M	30.79M	21.66M	8.78M	7.02M	13.35M	18.97M	13.12M	17.50M	20.62M	9.87M	12.92M	13.52M	10.73M	7.16M	5.49M	4.79M	3.62M	3.59M	3.56M	1.38M	2.16M	1.40M	178.03K	-559.30K	-1.62M	-300.00K	8.70M	5.60M	5.10M	5.90M	4.60M
Gross Profit Ratio	34.67%	46.43%	77.73%	78.24%	72.28%	68.10%	55.36%	51.40%	60.33%	58.18%	53.58%	55.65%	58.86%	53.14%	58.16%	49.08%	41.86%	37.04%	37.03%	42.93%	41.03%	39.67%	42.31%	20.52%	37.49%	29.70%	3.27%	-19.18%	-78.50%	-13.64%	53.70%	44.80%	45.54%	45.04%	42.99%
Research & Development	12.81M	51.20M	70.65M	32.69M	16.94M	13.74M	10.85M	3.50M	99.39K	219.82K	5.58K	4.75K	5.28K	10.93K	381.00	105.92K	284.22K	208.61K	210.88K	273.78K	179.20K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	361.09K	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	31.18M	48.06M	43.17M	20.67M	14.50M	14.35M	14.82M	11.02M	8.66M	12.13M	9.14M	7.49M	9.63M	6.23M	6.43M	7.01M	7.04M	5.89M	4.82M	5.71M	4.46M	4.89M	4.93M	1.85M	2.97M	3.14M	2.90M	3.04M	2.99M	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	54.27K	88.87K	0.00	58.12K	221.72K	52.95K	332.76K	220.18K	191.15K	223.80K	179.87K	218.50K	123.10K	47.60K	36.53K	43.83K	129.16K	0.00	0.00	433.82K	1.64M	2.98M	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	31.18M	48.06M	43.17M	20.67M	14.50M	14.35M	14.82M	11.07M	8.75M	12.13M	9.20M	7.71M	9.68M	6.56M	6.65M	7.20M	7.26M	6.07M	5.04M	5.83M	4.51M	4.92M	4.97M	1.98M	2.97M	3.14M	3.33M	4.68M	5.97M	8.00M	10.70M	8.10M	6.20M	7.10M	3.70M
Other Expenses	-1.22M	2.09M	-316.06K	-8.71M	14.10M	-5.89M	-2.20M	15.51M	9.20M	9.20M	9.20M	7.71M	2.01M	1.69M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.26M	0.00	1.83M	1.28M	0.00	0.00	0.00	100.00K	500.00K	400.00K	300.00K	200.00K	100.00K
Operating Expenses	42.77M	101.35M	113.81M	53.36M	45.53M	28.09M	29.65M	14.58M	10.33M	12.35M	9.20M	7.71M	9.68M	6.57M	6.65M	7.30M	7.55M	6.28M	5.25M	6.10M	4.69M	4.92M	6.23M	1.98M	4.80M	4.43M	3.33M	4.68M	6.33M	8.10M	11.20M	8.50M	6.50M	7.30M	3.80M
Cost & Expenses	53.80M	110.08M	122.58M	66.70M	57.34M	38.24M	36.74M	21.21M	19.11M	25.99M	20.57M	21.67M	24.09M	15.27M	15.94M	21.33M	22.45M	18.44M	14.58M	12.47M	9.90M	10.38M	11.09M	7.32M	8.41M	7.74M	8.60M	8.15M	10.01M	10.60M	18.70M	15.40M	12.60M	14.50M	9.90M
Interest Income	0.00	0.00	4.37M	4.89M	4.62M	4.71M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.17K	55.98K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	607.47K	2.43M	4.37M	4.85M	4.62M	4.71M	2.95M	2.04M	3.32M	0.00	50.57K	0.00	296.18K	124.63K	3.98M	2.39M	0.00	74.91K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	268.18K	269.87K	209.60K	593.87K	783.64K	471.42K	452.05K	481.01K	422.87K	494.26K	589.34K	556.30K	461.45K	464.91K	466.54K	268.38K	217.09K	252.94K	333.63K	522.80K	1.09M	1.55M	1.01M	923.92K	1.83M	1.28M	533.99K	553.30K	675.08K	-100.00K	-500.00K	-400.00K	-300.00K	-200.00K	-100.00K
EBITDA	-36.20M	-89.98M	-79.23M	9.75M	-14.65M	-7.14M	-19.67M	-8.12M	4.92M	7.11M	4.51M	10.35M	11.40M	3.76M	4.69M	5.32M	3.40M	1.01M	573.99K	-1.11M	19.17K	210.53K	-1.66M	321.06K	-812.89K	-1.74M	-2.73M	-4.76M	-7.10M	-8.30M	-2.20M	-2.50M	-1.10M	-1.60M	800.00K
EBITDA Ratio	-214.38%	-552.10%	-211.47%	-38.93%	-34.62%	-20.24%	-131.57%	-44.52%	16.22%	21.64%	18.77%	33.21%	31.65%	18.08%	39.04%	26.99%	9.08%	6.19%	3.96%	-6.94%	0.94%	2.33%	-4.75%	2.98%	-16.61%	-39.07%	-50.15%	-163.37%	-340.18%	-377.27%	-13.58%	-20.00%	8.93%	-12.21%	7.48%
Operating Income	-36.92M	-93.78M	-83.22M	-5.44M	-14.75M	-6.44M	-20.87M	-8.49M	3.02M	6.62M	3.92M	9.79M	10.94M	3.30M	4.35M	4.72M	3.18M	875.91K	240.36K	-1.31M	-1.07M	-1.34M	-2.67M	-602.86K	-2.64M	-3.03M	-3.15M	-5.24M	-7.95M	-8.20M	-1.70M	-2.10M	1.30M	-1.40M	900.00K
Operating Income Ratio	-218.61%	-575.46%	-211.47%	-8.88%	-34.62%	-20.24%	-131.57%	-62.20%	13.64%	20.30%	16.02%	31.12%	31.23%	17.75%	19.57%	17.13%	12.42%	4.53%	1.62%	-11.75%	-12.09%	-14.76%	-31.72%	-8.98%	-45.75%	-64.17%	-57.80%	-179.62%	-385.12%	-372.73%	-10.49%	-16.80%	11.61%	-10.69%	8.41%
Total Other Income/Expenses	-160.93K	1.11M	-316.06K	-8.71M	-5.31M	-5.89M	-2.20M	-108.38K	-204.60K	68.63K	33.28K	144.26K	-147.91K	-63.37K	-125.03K	332.10K	1.02M	-7.00K	-12.35K	-44.40K	0.00	0.00	-1.26M	-568.40K	145.20K	100.18K	117.14K	79.53K	-252.61K	0.00	1.00M	0.00	600.00K	400.00K	200.00K
Income Before Tax	-37.08M	-92.67M	-83.54M	4.27M	-20.05M	-12.32M	-23.07M	-8.60M	2.81M	6.69M	3.96M	9.93M	10.79M	3.23M	4.22M	5.05M	4.20M	868.91K	228.01K	-1.33M	-1.07M	0.00	-3.93M	-1.17M	-2.49M	-2.93M	-3.03M	-5.16M	-8.20M	0.00	-1.50M	0.00	-800.00K	-1.00M	1.00M
Income Before Tax Ratio	-219.56%	-568.65%	-212.28%	6.96%	-47.08%	-38.74%	-145.43%	-63.00%	12.72%	20.51%	16.16%	31.58%	30.80%	17.41%	19.01%	18.34%	16.40%	4.50%	1.54%	-11.87%	-12.09%	0.00%	-46.67%	-17.44%	-43.23%	-62.05%	-55.65%	-176.89%	-397.36%	0.00%	-9.26%	0.00%	-7.14%	-7.63%	9.35%
Income Tax Expense	725.10K	480.21K	236.40K	-3.13M	-1.08M	-303.93K	866.10K	-1.99M	2.47M	2.34M	1.52M	-4.41M	-4.51M	-2.17M	-2.51M	-1.49M	-762.86K	-825.00K	-29.32K	58.51K	1.02M	1.04M	2.07M	447.43K	906.65K	624.13K	89.28K	291.21K	963.00K	100.00K	1.30M	1.60M	5.60M	100.00K	600.00K
Net Income	-37.80M	-93.15M	-83.78M	7.39M	-18.97M	-12.02M	-23.94M	-6.61M	344.73K	4.35M	2.43M	14.34M	15.30M	5.40M	6.74M	6.54M	4.97M	1.69M	282.03K	-1.36M	-2.02M	-2.37M	-3.48M	-1.17M	-3.69M	-3.75M	-3.36M	-5.61M	-8.66M	-8.30M	-3.00M	-3.70M	-4.30M	-1.50M	300.00K
Net Income Ratio	-223.86%	-571.60%	-212.88%	12.07%	-44.55%	-37.79%	-150.89%	-48.42%	1.56%	13.33%	9.93%	45.59%	43.67%	29.08%	30.32%	23.73%	19.38%	8.77%	1.90%	-12.15%	-22.87%	-26.20%	-41.36%	-17.44%	-63.99%	-79.53%	-61.59%	-192.33%	-419.54%	-377.27%	-18.52%	-29.60%	-38.39%	-11.45%	2.80%
EPS	-0.28	-1.10	-1.05	0.10	-0.28	-0.19	-0.44	-0.19	0.01	0.15	0.09	0.51	0.55	0.20	0.25	0.25	0.18	0.06	0.01	-0.06	-0.10	-0.12	-0.21	-0.08	-0.29	-0.34	-0.34	-0.66	-1.30	-1.39	-0.62	-0.96	-1.24	-0.45	0.14
EPS Diluted	-0.28	-1.10	-1.05	0.09	-0.28	-0.19	-0.44	-0.19	0.01	0.15	0.08	0.50	0.53	0.19	0.24	0.24	0.18	0.06	0.01	-0.06	-0.10	-0.12	-0.21	-0.08	-0.29	-0.34	-0.34	-0.66	-1.30	-1.39	-0.62	-0.96	-1.24	-0.45	0.14
Weighted Avg Shares Out	134.88M	84.97M	80.12M	76.27M	66.75M	63.32M	53.86M	34.41M	28.67M	28.53M	28.52M	28.38M	27.69M	27.29M	26.98M	25.65M	26.12M	24.95M	23.80M	21.67M	19.33M	19.02M	16.24M	14.63M	12.76M	10.89M	10.00M	8.51M	6.64M	5.97M	4.84M	3.85M	3.47M	3.33M	3.28M
Weighted Avg Shares Out (Dil)	134.88M	84.97M	80.12M	83.80M	66.75M	63.32M	53.86M	34.64M	28.93M	28.92M	28.87M	28.73M	28.93M	28.97M	28.55M	27.81M	27.98M	26.40M	26.49M	21.67M	19.33M	19.02M	16.24M	14.63M	12.76M	10.89M	10.00M	8.51M	6.64M	5.97M	4.84M	3.85M	3.47M	3.33M	3.28M

Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023

August 3, 2023globenewswire.com

MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for breast cancer and for viral acute respiratory distress syndrome (ARDS), today announced it will host a...

Veru Inc.'s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

June 21, 2023globenewswire.com

Research grants from U.S. Department of Defense (DoD) and National Cancer Institute's Research Project Grant (NCI R01) awarded to UTHSC to study new types of targeting agents for multiple cancer indications with significant unmet need

Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

June 1, 2023globenewswire.com

MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the...

Veru to Present at the Jefferies Healthcare Conference

May 24, 2023globenewswire.com

MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced that...

Veru Inc. (VERU) Q1 2023 Earnings Call Transcript

May 11, 2023seekingalpha.com

Veru Inc. (NASDAQ:VERU ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer & President Michele Greco - Chief...